高血壓 高尿酸 慢性腎病 胰島素 https://2019medicinenote.blogspot.com/2019/12/blog-post_57.html . 糖尿病相關筆記~目錄 https://2019medicinenote.blogspot.com/2020/01/blog-post_4.html

2026年7月16日 星期四

野外與登山醫學-台灣研究-三天行程爬玉山的兒童發生AMS機率高於成人

2026-07-17 13:15
台灣之前的研究. 爬玉山的成人發生AMS的機率 36%
這篇是2016年發表在旅遊醫學期刊的研究, 研究對象是 96 名11-12歲健康兒童, 以三天行程爬玉山. 59% 發生AMS. 近期感冒會增加AMS機率

Incidence and risk factors associated with acutemountain sickness in children trekking on JadeMountain, Taiwan

Abstract
Background:
Acute mountain sickness (AMS) is a pathophysiological symptom complex that occurs in high-altitude areas. The incidence of AMS on Jade Mountain, the highest peak in Taiwan (3952 m), has been reported to be 36%. There is a lack of data in children trekking at altitude in Taiwan. The purpose of this study was to determine the incidence, risk factors and symptoms of AMS in children trekking on Jade Mountain, Taiwan. 
Methods: 
This prospective cohort study included a total of 96 healthy non-acclimatized children aged 11–12 years who trekked from an elevation of 2600–3952 m in 3 days. The Lake Louise AMS score was used to record symptoms associated with AMS. 
Results: 
AMS were reported in 59% of children trekking on Jade Mountain over a 3 day period. AMS incidence increased significantly with increasing altitude. The most common AMS symptom was headache, followed by fatigue or weakness, difficulty sleeping, dizziness or lightheadedness and gastrointestinal symptoms. Children who had experienced upper respiratory infection (URI) within the 7 days before their trek tended to have a greater risk for development of AMS. AMS incidence did not significantly differ according to gender, recent acute gastroenteritis, menstruation and body mass index. 
Conclusions: 
The incidence of AMS in children trekking on Jade Mountain is greater than that observed in adults, and was associated with altitude and recent URI.

Hypoxia and Hypoxemia 缺氧與低血氧區別

2026-07-17 12:03中午
關於缺氧, Hypoxia 與 hypoxemia 差異可以參考這篇
Hypoxia and Hypoxemia (from StatPerls)

名詞解釋
Oxygen saturation 血氧飽和度. 是指血紅素中有攜帶氧氣的比例
Hypoxia, 可翻譯為缺氧. 是指血流所攜帶的氧氣不足以供應組織氧氣需求. 是組織層面的缺氧, 原因可以是血流不足或血中氧氣不足引起
hypoxemia 可翻譯為低血氧. 是指血中氧氣濃度降低.
PaO₂ 動脈血中氧分壓 (the partial pressure of oxygen in arterial blood.)
Pulse oximetry 血氧機. 測得的是血氧氣飽和度. 人體的氧氣輸送主要是靠血紅素(印象是97%靠血紅素. 3% 靠血漿), 貧血的人. 即使血氧飽和度正常. 因同量血流能攜帶的氧氣量下降. 比一般人容易發生組織缺氧
同樣的原因. 動脈血中氧分壓即使正常. 在貧血的狀況仍會降低血液攜帶氧氣能力. 發生組織缺氧的機率也會增加
 
Hypoxia occurs when oxygen is insufficient at the tissue level to maintain adequate homeostasis, stemming from various causes such as hypoventilation, ventilation-perfusion mismatch, or right-to-left shunting. Hypoxia can manifest acutely or chronically, with varying presentations from dyspnea to tachypnea. Evaluation methods include pulse oximetry, arterial blood gas analysis, imaging, and PaO2:FiO2 ratio calculation for acute hypoxia. Conversely, pulmonary function tests, overnight oximetry, and other relevant assessments.

Introduction

Hypoxia occurs when oxygen is insufficient at the tissue level to maintain adequate homeostasis, stemming from various causes such as hypoventilation, ventilation-perfusion (V/Q) mismatch, or right-to-left shunting. This condition can arise from inadequate oxygen delivery to the tissues due to either low blood supply or low oxygen content in the blood, also known as hypoxemia.

Hypoxia can manifest across a spectrum of intensity, ranging from mild to severe, and present in acute, chronic, or mixed acute and chronic forms. The response to hypoxia varies among tissues—while some tissues can tolerate certain forms of hypoxia or ischemia for extended periods, others are significantly impaired by low oxygen levels

Etiology

At the tissue level, 2 primary causes of hypoxia arise—low blood flow to the tissue or low oxygen content in the blood (hypoxemia). Hypoxemia should be differentiated as a cause of hypoxia. Oxygen is transported by hemoglobin within red blood cells, and efficient ventilation relies on the direct contact between red blood cells and alveoli, facilitating diffusion. This process may be compromised at any of the following 3 points—blood flow to the lung (perfusion), airflow to the alveoli (ventilation), and gas exchange through the interstitial tissue (diffusion).

As mentioned below, hypoxia can arise from various underlying causes, each with distinct etiologies and mechanisms.

Reduced oxygen tension: As in cases of high altitude.

Hypoventilation: Hypoventilation can result from various factors, including:

  • Proximal airway obstruction, such as laryngeal edema or foreign body inhalation.
  • Distal airway obstruction, as seen in bronchial asthma or chronic obstructive pulmonary disease (COPD).
  • Impaired respiratory drive, as observed in cases of deep sedation or coma.
  • Restricted chest wall movement, which is evident in conditions such as obesity hypoventilation syndrome, circumferential burns, massive ascites, or ankylosing spondylitis.
  • Neuromuscular diseases include myasthenia gravis, muscular dystrophy, amyotrophic lateral sclerosis, or phrenic nerve injuries.

V/Q mismatch: This imbalance also leads to hypoxia in 2 ways, as mentioned below.

  • Decreased V/Q ratio: Decreased V/Q ratio, caused by impaired ventilation or high perfusion, as seen in conditions such as chronic bronchitis, obstructive airway disease, mucus plugs, and pulmonary edema, results in compromised ventilation and a reduction in the V/Q ratio.
  • Increased V/Q ratio: In cases of increased V/Q ratio, characterized by impaired perfusion as seen in conditions such as pulmonary embolism, or increased ventilation such as in emphysema with large bullae in the lungs, the available surface area for gas exchange diminishes. This results in higher ventilation than perfusion, leading to a high V/Q ratio.

Right-to-left shunt: Right-to-left shunt occurs when blood bypasses the lungs without oxygenation by crossing from the right to the left side of the heart. Causes include:

  • Anatomic shunts: Blood bypasses the alveoli, as seen in intracardiac shunts such as atrial septal defect (ASD), a ventricular septal defect (VSD), or a patent ductus arteriosus (PDA), pulmonary arteriovenous malformations, fistulas, and hepato-pulmonary syndrome.
  • Physiologic shunts: Blood passes through non-ventilated alveoli, such as pneumonia, atelectasis, and acute respiratory distress syndrome (ARDS).

Impaired diffusion of oxygen: Oxygen diffusion between the alveolus and the pulmonary capillaries is hindered, typically due to interstitial edema, inflammation, or fibrosis. Clinical examples encompass conditions like pulmonary edema and interstitial lung disease.

兒童肺動脈高壓

2026-07-16 15:41
閱讀兒童高海拔疾病的時候發現 uptodate 建議的高海拔肺水腫治療藥物包含 amlodipine. 這個藥物通常不列為 HAPE 預防或治療選項. 因此查詢了一下相關資料. 可能與過去對兒童肺動脈高壓的治療有關. 

Pulmonary artery hypertensioin 肺動脈高壓 縮寫 PAH
肺動脈高壓屬於較罕見的疾病(每10萬人口有2.28例). 兒童肺動脈高壓相較於成人肺動脈高壓又更罕見(每10萬人 0.98-2 例). 成人及兒童的盛行率及發生率在下面有列出. 

兒童肺動脈高壓治療與預後 from uptodate
肺動脈高壓治療
肺動脈高壓的治療包括使用肺血管擴張劑,這些藥物可以合併使用或單獨使用。用於治療肺動脈高壓(PAH)的藥物包括(表2):
●鈣離子通道阻斷劑(CCB;例如,Nifedipine 硝苯地平、Amlodipine 氨氯地平、diltizium 地爾硫卓-但不包括 verapamil 維拉帕米
●5 型磷酸二酯酶抑制劑(PDE-5 抑制劑;例如,西地那非他達拉非
●內皮素受體拮抗劑(ERA;例如,波生坦安立生坦馬西替坦
●前列環素類似物(例如,依前列醇曲前列尼爾伊洛前列素

兒童肺動脈高壓的標靶治療主要依據成人臨床試驗、有限的兒童臨床試驗和觀察性研究數據以及臨床經驗[ 2,3 ]。西地那非波生坦是僅有的兩種同時獲得美國食品藥物管理局(FDA)和歐洲藥品管理局(EMA)核准用於治療兒童肺動脈高壓的藥物。
此外,他達拉非(用於2歲及以上兒童)和安立生坦(用於8歲及以上兒童)也獲得了EMA的批准。
其他大多數用於治療兒童肺動脈高壓的肺血管擴張劑均屬於「超適應症用藥」。

成人肺動脈高壓
全球肺動脈高壓盛行率可以參考這篇. 2025年1月刊登在 LANCET . 作者是阿聯酋哈里發大學的醫師
Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
肺動脈高壓定義:
靜止狀態下平均肺動脈壓超過20 mmHg,肺毛細血管楔壓低於15 mmHg,以及透過右心導管檢查獲得的肺血管阻力至少為2 Wood單位

2021年,全球肺動脈高壓的患病人數粗估為19.2萬例
其中女性 11.9萬例(62%) 男性 7.31萬例(38%)

PAH的年齡標準化盛行率為每10萬人2.28例
1990年的年齡標準化盛行率為每10萬人2.30例

2021年,全球女性PAH盛行率高於男性,
每10萬女性PAH病例數為2.75例(2.24–3.39)
每10萬男性PAH病例數為1.78例(1.44–2.17)

依年齡標準化後,各地區的盛行率
南亞的每10萬人口1.71例(1.38–2.09)
西歐的每10萬人口3.56例(2.92–4.35)

全球肺動脈高壓的盛行率隨年齡增加而增加
2021年盛行率每十萬人 2.28 例
2021年死亡率每十萬人 0.27 例
75-79歲族群的盛行率最高- 每10萬人口7.99例
2021年全球死於肺動脈高壓的人數約 2.2萬例

兒童肺動脈高壓
相較於成人. 兒童肺動脈高壓屬於罕見疾病. Google 查詢到的資料
兒童肺動脈高壓盛行率每百萬人 9.8-32.6例.
兒童肺動脈高壓發生率每年每百萬人 1.6-8.1 例

Pediatric pulmonary hypertension (PH) is a rare condition. Depending on geographical region and inclusion criteria, the global prevalence is estimated at 9.8 to 32.6 cases per million children. The incidence ranges from 1.6 to 8.1 new cases per million children per year.

大陸有一篇研究統計了過去兒童肺動脈高壓的盛行率. 作者是武漢市第六醫院呼吸與危重症醫學科的醫師
Pediatric pulmonary arterial hypertension: global epidemiology and disease burden during the period 1990 to 2021
這篇是2025年8月刊載於 Frontiers in Cardiovascular Medicine 期刊總部在瑞士. Impact factor 3.0

兒童PAH的發生率在每百萬兒童為1.6至3.0例,盛行率在每百萬名兒童為9.8至20例.

0-14歲盛行率相對穩定
1990年 十萬分之 0.44
2021年 十萬分之 0.43

其中 10-14歲有較高的盛行率
1990年 十萬分之 0.66
2021年 十萬分之 0.65

女性年發生率較男性高.
每年會增加 0.12% 患者.

Globally, the age-standardized prevalence rate (ASPR) of pediatric PAH in children aged 0–14 years showed a relatively stable, from 0.44 per 100,000 in 1990 to 0.43 per 100,000 in 2021. Females exhibited higher age-standardized incidence rates (ASIR) and ASPR compared to males. The ASIR of pediatric PAH increased modestly, with an average annual growth of 0.12%. Children aged 10–14 years had the highest prevalence, with rates of 0.66 per 100,000 in 1990 and 0.65 per 100,000 in 2021. In contrast, newborns aged 0–6 days experienced the highest mortality rates (34.16 and 13.67 per 100,000) and DALYs rates (3,073.56 and 1,229.88 per 100,000) during the same period. Countries with high-middle SDI levels had the highest ASPR, while high-SDI countries reported the lowest age-standardized mortality rate and age-standardized disability rate.

Cardiovascular risks: New insights from Framingham -1988

2026-08-27 17:16 (下面中文使用 google 翻譯) 管心血管疾病仍是美國的主要死因,但其發生率在過去20年中持續下降。這一趨勢主要歸功於心血管危險因子的檢測和管理水平的提高。弗雷明漢心臟研究的開創性工作自1940年代末開始追蹤受試者,有助於揭示諸如高齡、高血壓...